Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Gains from Investment Securities (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Gains from Investment Securities readings, the most recent being $3000.0 for Q1 2026.

  • Quarterly Gains from Investment Securities fell 94.79% to $3000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7000.0 through Mar 2026, down 87.85% year-over-year, with the annual reading at $6.9 million for FY2025, 46.3% up from the prior year.
  • Gains from Investment Securities hit $3000.0 in Q1 2026 for DiaMedica Therapeutics, down from $5.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.7 million in Q2 2025 and bottomed at $1000.0 in Q4 2022.
  • Average Gains from Investment Securities over 5 years is $1.8 million, with a median of $450410.0 recorded in 2023.
  • The largest annual shift saw Gains from Investment Securities soared 5662.5% in 2025 before it crashed 94.79% in 2026.
  • DiaMedica Therapeutics' Gains from Investment Securities stood at $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then soared by 200.0% to $3000.0 in 2024, then skyrocketed by 190148.13% to $5.7 million in 2025, then crashed by 99.95% to $3000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Gains from Investment Securities are $3000.0 (Q1 2026), $5.7 million (Q3 2025), and $6.7 million (Q2 2025).